US FDA lowers risk classification for cardiac allograft gene expression profiling tests
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has classified cardiac allograft gene expression profiling test systems as medium-risk (Class II) devices1 and established special controls that would provide a reasonable assurance of safety and effectiveness of such products2,3.